Of the 354 substances designated as class I under the Pollutant Release and Transfer Register (PRTR) law in Japan, we reviewed the sensitization data of the selected 144 substances and analyzed it from various aspects comparing human and animal data, determining the relationship between skin sensitization and chemical structure and comparing the various international organizations. Although most of them were expected to be hazardous substances, 49 out of the 144 substances lacked both human and animal sensitization data. Positive substances accounted for 69% and 42% of the substances for which sensitization data were available in the case of humans and animals, respectively. A correlation was observed between the chemical structures of the substances and sensitization, despite the relatively few substances examined in this study and the limited homogeneity of the collected data. In particular, epoxides clearly had sensitizing potentials and more than half of carboxylic esters or dicarboxyl anhydrides, aliphatic aldehydes, and aromatic compounds with at least two hydroxyl groups also had sensitizing potentials. Also, this study clearly demonstrated the lack of consistency across the sensitization assessment criteria adopted by different countries or among those adopted by the same country on the basis of different laws or administrative measures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.yrtph.2009.05.020 | DOI Listing |
Background: In high-burden settings, most tuberculosis (TB) transmission likely occurs outside the home. Our qualitative study in Zambia explored the acceptability and preferences for designing TB active case finding (ACF) strategies to reach non-household contacts of people with TB.
Methods: We conducted 56 in-depth interviews with persons with TB ( = 12), TB healthcare workers (HCWs) ( = 10), TB lay HCWs ( = 10), and leaders/owners ( = 12) and attendees ( = 12) of community venue types identified as potential TB transmission locations.
BMC Health Serv Res
January 2025
Sydani Initiative for International Development, FCT, Abuja, Nigeria.
Background: Evidence from literature has established that tracing lost to follow-up clients is an effective strategy for complementing other mechanisms for infectious disease control like human immunodeficiency virus (HIV), tuberculosis, and other diseases such as Ebola. As a long-standing successful public health method of optimizing acceptance and/or adherence to infectious disease treatment tracing lost to follow-up clients is usually carried out by manually investigating individuals who absconded or are absent from treatments designed to manage and/or promote their health status. This study seeks to explore the role of mobile teams in tracing clients lost to follow-up for immunization.
View Article and Find Full Text PDFBMC Med Ethics
January 2025
Department of Pharmacy, Makerere University, Kampala, Uganda.
Background: Shared decision-making in healthcare is a collaborative process where patients are supported to make informed decisions according to their preferences. Healthcare decisions affect patients' lives which necessitates patients to participate in decisions concerning their health. This study explored experiences and ethical issues related to shared decision-making in a rural healthcare setting.
View Article and Find Full Text PDFNat Chem Biol
January 2025
Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.
RAF protein kinases are major RAS effectors that function by phosphorylating MEK. Although all three RAF isoforms share a conserved RAS binding domain and bind to GTP-loaded RAS, only ARAF uniquely enhances RAS activity. Here we uncovered the molecular basis of ARAF in regulating RAS activation.
View Article and Find Full Text PDFCell Death Discov
January 2025
Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
TP53 mutations are recognized to correlate with a worse prognosis in individuals with non-small cell lung cancer (NSCLC). There exists an immediate necessity to pinpoint selective treatment for patients carrying TP53 mutations. Potential drugs were identified by comparing drug sensitivity differences, represented by the half-maximal inhibitory concentration (IC50), between TP53 mutant and wild-type NSCLC cell lines using database analysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!